Stocks · News reference
Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 8:03 PM
- Checked
- Aug 27, 2026, 8:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed
Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity
Read original at benzingaCanaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29
Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.
Read original at benzinga